Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol in major depressive disorder
NCT06360419Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of solriamfetol in major depressive disorder (MDD), sponsored by Axsome Therapeutics, Inc.. Started Mar 2024; status: completed.
02
Drugs
solriamfetol
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06360419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360419.